Locations
Carmel, IN, USA · Charlottesville, VA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Other
founded in
1996
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company is advancing its lead candidate, sabirnetug (ACU193), a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs), which are believed to play a significant role in the progression of Alzheimer’s. Acumen aims to provide disease-modifying benefits and symptomatic relief for patients with early Alzheimer’s disease. With a strong pipeline and ongoing clinical trials, including the Phase 2 ALTITUDE-AD trial, Acumen is positioned to make a substantial impact in the Alzheimer’s treatment landscape.
Something looks off?On-site & Remote